UK drug companies must disclose funding of patients' groupsBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7533.69-a (Published 12 January 2006) Cite this as: BMJ 2006;332:69
- Michael Day
Drug companies must make public their involvement with patients' advocacy groups, under a revised industry code of practice introduced in the United Kingdom this month.
From 1 January firms are expected to name all patients' organisations that receive their financial support. They must also set out details of such relationships and any funding provided, say the new rules of the Association of the British Pharmaceutical Industry. The update …